KJAER, TANJA MARIA ROSENKILDE,KRUSE, THOMAS,MYGIND, PER HOLSE,BRINCH, KAROLINE SIDELMANN,KJAERULFF, SOEREN,ANDERSEN, BIRGITTE
申请号：
NZ59046809
公开号：
NZ590468A
申请日:
2009.07.17
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Discloses the use of human beta defensin peptides (1-4), encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, in the manufacture of a medicament adapted for parenteral administration in the treatment of an inflammatory bowel disease. The medicament may be administered subcutaneously or intravenously in a daily dosage from 0.001 mg/kg body weight to about 10 mg/kg body weight, where the use of the medicament results in a reduction of TNF-alpha activity is reduced in the treated tissues.
